Gilead Names New SVP for Hematology, Oncology Unit

From DCAT Value Chain Insights (VCI)

By People On The Move posted 01-11-2017 10:37


Gilead Sciences has named Alessandro Riva, MD, as new senior vice president, hematology and oncology therapeutic area head. Dr. Riva will report to John McHutchison, MD, executive vice president, clinical research, and will have responsibility for Gilead’s hematology and oncology programs. Alessandro will also join Gilead’s executive committee.

Dr. Riva joins Gilead from Novartis Oncology, where he served as head, global oncology development. He was also a member of the Novartis Oncology division executive committee, development committee, translational and early development committee, and innovation management board. During his 12 year tenure at Novartis he was involved in several worldwide drug approvals.

Prior to joining Novartis, Dr. Riva co-founded the Breast Cancer International Research Group (BIRG) and Cancer International Research Group (CIRG), for which he served as chief executive officer and chief medical officer. He served in clinical development leadership positions at Farmitalia Carlo Erba, Rhone-Poulenc, and Aventis.

Source: Gilead Sciences


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription